Johnson & Johnson's Spravato is within touching distance of an approval in the EU after the closely watched antidepressant derived from ketamine got a positive opinion from European Medicines Agency advisors.
J&J's Spravato Set For EU Launches Soon
Ketamine-Like Antidepressant Backed By CHMP
If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.
More from Neurological
More from Therapy Areas
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.